Mainstay Capital Management LLC ADV Sells 4,865 Shares of Amgen Inc. $AMGN

Mainstay Capital Management LLC ADV cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 47.1% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,454 shares of the medical research company’s stock after selling 4,865 shares during the period. Mainstay Capital Management LLC ADV’s holdings in Amgen were worth $1,539,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in AMGN. Evelyn Partners Investment Management LLP bought a new position in shares of Amgen during the 2nd quarter worth $32,000. Howard Hughes Medical Institute bought a new stake in shares of Amgen in the second quarter valued at about $32,000. Cloud Capital Management LLC bought a new stake in shares of Amgen in the third quarter valued at about $34,000. Saranac Partners Ltd purchased a new stake in Amgen in the third quarter worth about $37,000. Finally, AXS Investments LLC purchased a new stake in Amgen in the third quarter worth about $42,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analysts lifted Amgen’s fair value amid optimism around obesity candidate MariTide and execution, which supports a stronger medium-term outlook for earnings. How The Amgen (AMGN) Narrative Is Shifting With MariTide Hopes And Exclusivity Concerns
• Positive Sentiment: Billionaire Ken Fisher increased his Amgen stake, a signal of institutional confidence that can support investor sentiment. Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position
• Neutral Sentiment: Short-interest print shows zero shares (and NaN change), which appears to be a reporting error; it doesn’t offer actionable insight into current positioning.
• Neutral Sentiment: Sector/biotech financing note — Crossbow raised $77M for an oncology T‑cell engager program; industry capital flow can influence sentiment but it doesn’t directly affect Amgen’s fundamentals. Crossbow raises $77M for new cancer immunotherapies
• Negative Sentiment: Report says Amgen will join TrumpRx and offer an ~80% discount on Amjevita — a move that could pressure revenue/margins for that product and raise investor concern about pricing concessions. Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
• Negative Sentiment: Market headlines reporting that AMGN closed lower amid a broader market uptick — confirms the stock is underperforming today and may be reacting to the items above. Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Analyst Ratings Changes

A number of research analysts have commented on AMGN shares. Freedom Capital downgraded shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. HSBC reaffirmed a “buy” rating and issued a $425.00 price target on shares of Amgen in a research report on Wednesday, December 10th. The Goldman Sachs Group increased their price objective on shares of Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Truist Financial boosted their price objective on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus target price of $354.00.

Amgen Stock Performance

Shares of Amgen stock opened at $351.48 on Thursday. The company has a market capitalization of $189.47 billion, a PE ratio of 24.70, a P/E/G ratio of 3.58 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company has a 50-day simple moving average of $359.46 and a two-hundred day simple moving average of $326.94. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same period in the prior year, the firm posted $5.31 earnings per share. The company’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s dividend payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.